Teva Canada has issued a recall for specific batches of Teva-Pregabalin 150 mg capsules due to potential contamination with sertraline, as discovered during routine testing. The affected lots are identified by the numbers 100070495 and 100068913. These capsules were initially distributed in Canada in September 2025 and carry an expiration date of July 31, 2027.
Individuals who are hypersensitive or allergic to sertraline may encounter adverse effects or a severe allergic response, including anaphylaxis, even with minimal exposure, according to information provided by Health Canada in a recall notice. Anaphylactic reactions have the potential to be life-threatening. Health Canada has advised consumers in possession of products from the specified lots to promptly return them to a pharmacy.
Pregabalin is a prescribed medication utilized for managing nerve damage-induced pain, while sertraline is another prescription drug prescribed for alleviating symptoms related to depression, obsessive-compulsive disorder, and panic disorders. Teva Canada, headquartered in Toronto, indicated in its recall notice released on Friday that this action is a precautionary step.
